Synthes signs license and development agreement with Kuros

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications has signed a license and development agreement with Synthes, Inc. a leading global medical device company.

Under the terms of the agreement Synthes and Kuros will work together to commercialize Kuros' synthetic matrix technology in certain fields.

Commenting on today's announcement, Mr. Didier Cowling, CEO of Kuros, said: "We are delighted to have signed this deal related to our synthetic matrix technologies with Synthes.  Partnering our products with leading marketing partners is a key element of Kuros' strategy and we are looking forward to a productive working relationship with Synthes."

Michel Orsinger, President and CEO of Synthes, commented on the partnership: "The Kuros partnership is an important addition to Synthes goal of being a total solutions provider for our customers. The partnership will strengthen both Kuros and Synthes commitment to develop patient focused clinical solutions."

Kuros has a broad platform of technologies related to biomaterials and the combination of biomaterials with bioactive molecules.  This platform has the potential to be used across many fields and includes synthetic matrices either alone or in combination with bioactives.